<DOC>
	<DOCNO>NCT00419159</DOCNO>
	<brief_summary>To assess safety efficacy weekly ( 70 mg per week ) daily ( 10 mg per day ) everolimus patient metastatic colorectal cancer whose cancer progress despite prior treatment target therapy chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Everolimus Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 18 year old . Patients metastatic colorectal cancer ( CRC ) . Patients must sufficient obtainable tumor tissue biomarker analysis original surgical resection . Patients document disease progression within 6 month recent dose chemotherapeutic regimen . Patients least one measurable lesion . Adequate bone marrow function . Adequate liver function . Adequate renal function . Patients life expectancy &gt; 3 month . Patients World Health Organization ( WHO ) performance status 0 , 1 , 2 . Women childbearing potential must negative serum pregnancy test 72 hour prior administration first study treatment . Patients give write informed consent obtain accord local guideline . Exclusion criterion : Patients currently receive anticancer agent receive within 4 week prior study entry . Patients previously receive RAD001 . Patients know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients . Chronic treatment steroid another immunosuppressive agent . Patients untreated central nervous system ( CNS ) metastases neurologically unstable CNS metastasis . HIV seropositivity . Patients active , bleeding diathesis . Patients may use enoxaparin . Patients severe and/or uncontrolled medical condition condition could affect participation study . Patients history another primary malignancy &lt; 3 year , exception nonmelanoma skin cancer , carcinoma situ uterine cervix . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . Patients use investigational agent receive investigational drug ≤ 4 week prior first study treatment . Patients unwilling unable comply protocol . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>metastatic colorectal adenocarcinoma</keyword>
	<keyword>anti-EGFR antibody</keyword>
</DOC>